Press Room
Ulf Grawunder to leave 4-Antibody
4-Antibody AG today announced that Dr Ulf Grawunder, the company’s Chief Scientific Officer and a co-founder of the company will be leaving 4-Antibody in the New Year.
more...4-Antibody AG Meets Next Milestone in Boehringer Ingelheim Collaboration
more...4-Antibody AG Forms Collaboration with Human Genome Sciences
more...4-Antibody AG Forms Multi-target Oncology Research and Development Alliance with the Ludwig Institute
4-Antibody AG today announced the signing of a multi-target research alliance with the Ludwig Institute for Cancer Research (LICR). Under the terms of the deal, the focus of the research and clinical development alliance will be on a series of molecular targets which are important in the suppression of the immune response in cancer. Financial details were not disclosed.
more...4-Antibody AG to Relocate to New Labs in Basel
4-Antibody AG, a leading Swiss antibody discovery company today announced that the Company will be relocating its Basel head offices and labs in June, 2011 to the newly opened Technology Park Basel, which is part of the Stücki Business Park in Basel-Kleinhüningen.
more...4-Antibody AG Meets First Milestone in Boehringer Ingelheim Partnership
The company today announced that it has achieved the successful completion of a first milestone in its ongoing collaboration with Boehringer Ingelheim.
more...4-Antibody AG Announces New Board Appointment
- Dr Thomas von Rüden, former CEO of DIREVO and leading industry exponent of in vitro antibody discovery & molecular evolution technologies
- 4-Antibody now pursuing additional corporate partnerships
4-Antibody AG Announces CEO Appointment
- Dr Robert F Burns – substantial experience in antibody discovery companies
- Company now pursuing additional corporate partnerships
Archive